Progen Pharmaceuticals (PGL)

Stock Code


Stock Exchange


Progen Pharmaceuticals Limited (PGL) is a biotechnology company engaged in discovering, developing as well as commercialising the small molecule pharmaceutical for cancer treatment. PGL was listed on the Australian Stock Exchange on the 22nd of December 1995. Its average annual revenue reaches approximately $2.6 million out of its issued capital of $63 million. Its headquarters is located in Queensland, Australia and to date; around 40 people are employed in the company.

Progen Pharmaceuticals Dividends

18 October, 2010 - 01:13

Study the list of historical dividends for Progen Pharmaceuticals. Dividends are a portion of company profits paid out to shareholders. If Progen Pharmaceuticals Limited has announced a dividend, you may be eligible to receive PGL dividends if the trader the company's stock on the ex-dividend date. Investors must have purchased the stock before the ex dividend date to be entitled to the dividend. The previous owner of the shares will receive the dividend if you buy the stocks on or after the ex dividend date.

Progen Pharmaceuticals (PGL): Loser

Progen Pharmaceuticals closed the week 19 per cent lower and is the worst performing stock on the Australian sharemarket last week after some trial results for its liver cancer drug.

Syndicate content

Recommended Websites